Your activity: 43 p.v.
< Back
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Treatment of EGFR inhibitor-induced acneiform rash

Treatment of EGFR inhibitor-induced acneiform rash
EGFR: epidermal growth factor receptor; CTCAE: Common Terminology Criteria for Adverse Events; SPF: sun protection factor; ADL: activities of daily living; PI: prescribing information.
* It is recommended that patients treated with EGFR inhibitors begin prophylactic rash therapy with doxycycline 100 mg twice a day or minocycline 100 mg daily and a low-potency topical steroid twice a day for the first 6 weeks of therapy.
Source:
  1. Modified from: Balagula E, Lacouture ME. Dermatologic toxicities. In: The MASCC Textbook of Cancer Supportive Care and Survivorship, Olver IN (Ed), Springer, New York 2010. Copyright © 2010; with kind permission from Springer Science + Business Media B.V.
  2. NCITCAE v.5 grade definitions reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed March 27, 2018).
Graphic 87010 Version 7.0